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Abstract
Background: Survival to older childhood with untreated, vertically acquired HIV infection, which was previously considered
extremely unusual, is increasingly well described. However, the overall impact on adolescent health in settings with high
HIV seroprevalence has not previously been investigated.
Methods and Findings: Adolescents (aged 10–18 y) systematically recruited from acute admissions to the two public
hospitals in Harare, Zimbabwe, answered a questionnaire and underwent standard investigations including HIV testing, with
consent. Pre-set case-definitions defined cause of admission and underlying chronic conditions. Participation was 94%. 139
(46%) of 301 participants were HIV-positive (median age of diagnosis 12 y: interquartile range [IQR] 11–14 y), median CD4
count = 151; IQR 57–328 cells/ml), but only four (1.3%) were herpes simplex virus-2 (HSV-2) positive. Age (median 13 y: IQR
11–16 y) and sex (57% male) did not differ by HIV status, but HIV-infected participants were significantly more likely to be
stunted (z-score,22: 52% versus 23%, p,0.001), have pubertal delay (15% versus 2%, p,0.001), and be maternal orphans
or have an HIV-infected mother (73% versus 17%, p,0.001). 69% of HIV-positive and 19% of HIV-negative admissions were
for infections, most commonly tuberculosis and pneumonia. 84 (28%) participants had underlying heart, lung, or other
chronic diseases. Case fatality rates were significantly higher for HIV-related admissions (22% versus 7%, p,0.001), and
significantly associated with advanced HIV, pubertal immaturity, and chronic conditions.
Conclusion: HIV is the commonest cause of adolescent hospitalisation in Harare, mainly due to adult-spectrum
opportunistic infections plus a high burden of chronic complications of paediatric HIV/AIDS. Low HSV-2 prevalence and high
maternal orphanhood rates provide further evidence of long-term survival following mother-to-child transmission. Better
recognition of this growing phenomenon is needed to promote earlier HIV diagnosis and care.
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Introduction
In industrialised countries trauma and behavioural disorders,
such as substance abuse, obesity, and sexually transmitted
infections account for most adolescent morbidity [1]. Chronic
diseases, trauma, oncology, and mental disorders account for the
majority of hospital admissions [2,3]. In Africa, research on
adolescent morbidity has been limited and has predominantly
focused on reproductive health, reflecting the high incidence of
sexually transmitted infections and obstetric problems among
young people [4,5].
As the HIV epidemic matures, long-term survival of HIV-
infected infants to adolescence following vertical transmission is
increasingly being recognised in African countries [6,7]. Symp-
tomatic HIV in older children and adolescents is a growing
problem in clinical practice but there are few data describing the
burden of HIV and its contribution to ill-health and mortality in
this age group [8,9]. In Southern Africa—the global region that
has experienced the most severe adult HIV epidemic [10]—a
substantial epidemic of HIV-infected long-term survivors of
vertical infection is anticipated during the coming decade, with
implications for adolescent health [11].
The spectrum of HIV-related disease varies considerably
between adults and children, but has not been well-defined for
adolescents. Although opportunistic infections predominate in all
age groups, chronic noninfectious clinical conditions may be more
prominent in HIV-infected adolescents than in adults and infants
[9–12]. In clinical studies of HIV infection, children are often
classified as aged 0–14 y and adults as 15–49 y, and thus
distinctive features of HIV-associated morbidity among adoles-
cents may be missed [13–15]. The aim of this study was
to investigate the prevalence of HIV and the spectrum of
morbidity among hospitalised adolescents aged 10–18 y in
Harare, Zimbabwe.
Methods
Study Participants
Harare Central Hospital and Parirenyatwa Hospital are the
main public sector hospitals in Harare and cater to two-thirds of
Harare’s population; the remaining one-third using private health
care facilities. The cost of hospitalisation in public sector facilities is
partially subsidised by the government. Malaria transmission does
not occur in Harare. Between September 2007 and April 2008,
patients admitted to either hospital were enrolled consecutively the
following day. Recruitment was limited to weekdays and to a
maximum of five patients per site per day for logistical ease.
Patients aged between 10 and 18 y admitted with any acute
medical or surgical condition, including trauma, were eligible.
Patients were excluded if moribund (i.e., likely to die within the
next few hours), requiring intensive care admission, or admitted
for obstetric or elective reasons, or previously enrolled into the
study.
Data Collection
Standardised investigations, summarised in Figure 1, includ-
ed social and clinical history, height, weight, and Tanner
puberty staging, and laboratory investigations (full blood count,
herpes simplex virus-2 [HSV-2] serology, provider-initiated
HIV testing and counselling [PITC], and CD4+ lymphocyte
[CD4+] count for HIV-infected participants). Where diagnostic
HIV testing was declined, participants and their guardians
were asked to consent to unreported HIV-testing for study
purposes. In addition, all participants with febrile, wasting, or
respiratory illness had a standardised infectious screen (blood
culture, blood films for malaria, cryptococcal antigen test-
ing [serum 1:8 dilution], two sputum specimens, and chest
radiography). If Pneumocystis jirovecii infection was suspected,
patients underwent sputum induction with nebulised hyper-
tonic saline.
Otherwise investigations followed standard hospital guidelines
including lumbar puncture for suspected meningitis and cerebral
computed tomography (CT) for focal neurological signs or
suspected encephalopathy. Participants were followed for the
duration of their hospital stay. Pre-set diagnostic algorithms
defined the definitive or presumptive cause of admission, and any
underlying chronic conditions (Text S1). The Adult World Health
Organization (WHO) Classification was used to stage HIV
infection [16].
Laboratory Methods
HIV serology used parallel testing with Abbott Determine and
SD Bioline. Discordant samples were resolved using Vironostika.
HSV-2 antibodies were detected using recombinant IgG antigen
(HerpeSelect, Focus Technologies; cut-off for positivity: OD.1.1).
CD4 counts were determined by flow cytometry (CyFlow counter,
Partec).
Blood culture used Myco/F Lytic (MFL, Becton Dickinson)
[17], inspected daily using a handheld UV Woods lamp. Bacterial
pathogens were identified by Gram staining and culture on
conventional media, with biochemical tests for confirmation.
Concentrated decontaminated sputum specimens and positive
blood cultures were examined under fluorescent microscopy
(Auramine-O) and cultured for mycobacteria (Lowenstein-Jensen
media). CSF and positive blood cultures were investigated for
Cryptococcus using India ink contrast staining, culture on Sabouraud
media, and cryptococcal antigen testing (IMMY, Alpha Labora-
tories). Induced sputum was stained with Grocott’s silver stain.
Thick blood films for malaria were examined using Giemsa
staining.
Statistical Analysis
Data were analysed with STATA software, version 10.0
(STATA Corporation). Continuous variables were compared
using Student’s t-test for normally distributed variables and Mann
Whitney U test for variables not normally distributed. Categorical
variables were compared using the Chi-squared (x2) or Fisher’s
exact test as appropriate. Z-scores for height- and weight-for-age
were calculated using British 1990 Growth Reference Curves,
which provide data over the age of 10 y [18]. z-Scores of ,22
were considered to represent stunting and wasting, respectively
[18].
Multivariate logistic regression was used for analysis of risk
factors for mortality [19]. Risk factors were considered in two
groups: socio-demographic (sex, age, orphanhood, difficulty
raising clinic fees, tuberculosis [TB] or illness in a household
member, food shortage, type of care-giver) and clinical (stage of
HIV, previous TB, antiretroviral therapy [ART] status, stunting,
wasting, pubertal delay, chronic disease, anaemia, poor perfor-
mance scores, self-perceived poor health, broad diagnosis
category). An initial model included socio-demographic factors
and all factors that reached statistical significance at p,0.05 were
included in a multivariate model. Factors that remained
independently associated with death were retained. The
association between each factor in the clinical group and death
was assessed by adding each factor into the multivariate model
that included the subset of independently significant socio-
demographic factors. The multivariate model was built that
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included the subset of socio-demographic factors in the first
multivariate model plus any clinical factors that were significant
after adjusting for the socio-demographic factors. The final
multivariate logistic regression model was reached by excluding
single factors sequentially until all remaining factors were
statistically significant.
Ethical Considerations
Written consent was obtained from all participants and from
guardians of participants aged below 16 y. Onward referral for
HIV care services was made for all testing HIV-positive.
Guardians were encouraged to disclose HIV status to HIV-
infected participants who did not know their status. Ethical
Figure 1. Study recruitment procedure for eligible participants.
doi:10.1371/journal.pmed.1000178.g001
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approval for the study protocol was obtained from the Ethics
Committees of the London School of Hygiene and Tropical
Medicine and the Joint Research Ethics Committee at the
University of Zimbabwe, Medical Research Council of Zimbabwe
(MRCZ), Harare and Parirenyatwa Hospital Ethics Committees
and the Institutional Review Board of the Biomedical Research
and Training Institute.
Results
Baseline Participant Characteristics and HIV Diagnosis
Of 1,025 total adolescent hospital admissions, 340 were eligible.
301 participants were recruited, with a refusal rate of 6%
(Figure 1). HIV prevalence was 46%. The median age was 13 y
(interquartile range [IQR]: 11–16), and 43% of participants were
female, with no significant association of age or sex by HIV status
(Table 1). Four (1.3%) participants tested HSV-2 positive, of
whom two were HIV-positive. HIV-infected participants were less
likely to be married (1% versus 9%, p,0.032), although the
comparison was based on small numbers.
The median age at diagnosis of HIV infection was 12 y (IQR:
11–14). Of the 139 participants who were HIV-positive, 86 (62%)
had tested prior to admission and knew their HIV status. Fifty
participants tested positive following PITC; of these, 17 had tested
HIV-positive previously but had not been told of their HIV
infection. All guardians, however, agreed to disclosure to the
participant with assistance of study counsellors. Only 18 (6%)
participants declined PITC, of whom three were HIV-positive on
Table 1. Baseline demographic, clinical, and growth characteristics of adolescents admitted to hospital (n= 301 unless specified
otherwise).
Characteristic n (%) of Participants p-Value
HIV-Infected, n=139 HIV-Negative, n=162
Demographic
Median age y (IQR)a 13 (11–15) 13 (11–16) 0.14
Female 65 (47) 65 (40) 0.25
Orphan (single or double) 111 (80) 58 (36) ,0.001
Mother dead or known to be HIV-infectedb 101 (73) 28 (17) ,0.001
Married 1(1) 8 (5) 0.032
Currently attending school 97 (70) 116 (72) 0.73
Previously tested for HIV 103 (74) 20 (12) ,0.001
HIV status already known by patientc 86 (62) 20 (12) ,0.001
Clinical
Previous TB treatment 61 (44) 3 (2) ,0.001
Previously hospitalised more than once (n= 294) 39 (29) 21 (13) ,0.001
WHO HIV clinical stage 3/4 115 (83) — —
Receiving antiretroviral therapy 45 (32) — —
Self-rated general health ‘‘fair’’ or ‘‘poor’’ 120 (86) 49 (30) ,0.001
Poor performance scores (WHO scale 3/4)d 64 (46) 20 (12) ,0.001
Median CD4+ count, cells/ml (IQR) (n=125)e,a 151 (57–328) — —
Growth and sexual development
Weight-for-age z,22 (n= 266)f 88 (72) 29 (20) ,0.001
Height-for-age z,22 (n= 263)g 63 (52) 32 (23) ,0.001
Body mass index z,22 (n=263)g 74 (73) 28 (27) ,0.001
Median mid-upper arm circumference, mm (IQR) (n= 296)a 172.5 (147–190.5) 204.5 (180–231) ,0.001
Tanner’s stage 1/2 (those $14 y) 21 (15) 4 (2) ,0.001
Occurrence of menarche (females only) 18 (28) 34 (52) 0.005
Self-reported consensual sexual debut (n=150)h 6 (9) 18 (22) 0.031
Self-reported forced sexual intercourse (n= 147)i 5 (8) 4 (5) 0.46
Data reported as percentage of patients and Chi-squared test used to compare HIV-infected and HIV-negative participants unless specified otherwise.
aData reported as median, not as percentage of patients and Mann Whitney U test used for comparison of medians between HIV-infected and HIV-negative participants.
bHIV-infected participants: 14 living mothers HIV-infected; HIV-negative participants: five living mothers HIV-infected.
c20 patients previously tested but HIV result not disclosed to patient.
dScale 3, bedridden, ,50% of the day during the last month; scale 4, bedridden, .50% of the day during the last month.
eData missing for 14 patients: six deaths before sample taken, one unable to venesect (severe wasting), seven inadequate volumes.
fData missing for 35 patients due to inability to stand: 20 too ill, eight fractured lower limb, four chronic disability, three pathology in lower limb (two joint infection/one
soft tissue infection).
gData missing for 38 patients: 35 as for b, plus two unable to stand upright, one acute confusion.
hData not available for151 patients (72 patients HIV-infected, 79 patients HIV-negative): 88 patients under 12 y, 63 patients too ill.
iData missing for 154 patients: 151 as for f, three patients question not answered (two HIV-negative and one HIV-infected).
doi:10.1371/journal.pmed.1000178.t001
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unreported HIV testing and are likely to remain unaware of their
HIV infection.
HIV-infected participants were significantly more likely to be
orphans, previously treated for tuberculosis, previously hospital-
ised more than once, stunted, and pubertally immature (Tanner’s
stage 1/2 for participants aged 14 y or older, and girls less likely to
have undergone menarche) (Table 1).
HIV-infected patients were profoundly immunosuppressed at
presentation: 83% had WHO stage 3 or 4 disease and 58% had
CD4+ T lymphocyte counts ,200 cells/ml. Only 44 (43%) of the
HIV-infected participants who had previously had an HIV test
were on ART (for a median duration of 121 d).
Causes of Hospitalisation and CD4+ Counts by
Diagnostic Group
The most frequent diagnosis among HIV-infected participants
was infection with tuberculosis, pneumonia, cryptococcosis, and
blood stream infections being the most frequent diagnoses. Among
HIV-negative participants, the commonest cause of admission was
trauma, followed by acute exacerbations of chronic medical
conditions, predominantly cardiac (Table 2). The median duration
of stay in hospital for HIV-infected participants was 9 d (IQR 6–
16 d) and for HIV-negative participants 7 d (IQR 4–18 d).
The highest median CD4 counts were found in patients
presenting with trauma or acute surgical causes conditions (455
and 628 cells/ml). Patients with blood stream infections, oesoph-
ageal candidiasis, and HIV-wasting syndrome had the lowest
median CD4 counts (85, 77, and 34 cells/ml, respectively).
Disease-Specific Microbiological Findings
113 (81%) and 41 (25%) of HIV-infected and HIV-negative
admissions (p,0.001) met criteria for the standardised infectious
screen (see Methods), of whom 20 (18%) and two (5%) had positive
blood cultures, respectively. The most frequently identified
pathogens in HIV-infected participants were nontyphoidal
Salmonella species and M. tuberculosis. Cryptococcus spp. were
identified in blood culture in three patients, in cerebrospinal fluid
(CSF) culture in five patients, and seven patients had a positive
cryptococcal antigen (CrAg) only.
There were 27 TB diagnoses of which 13 were pulmonary TB:
six were sputum smear- positive, one was culture-positive only,
and six were radiological diagnoses (smear- and culture-negative
pulmonary disease with failure to respond to broad-spectrum
antibiotics, but response to TB treatment at 1 mo). M. tuberculosis
was identified in blood culture in five patients.
Chronic Clinical Conditions
84 (28%) participants had underlying chronic medical condi-
tions other than HIV (26% in HIV-infected versus 29% in HIV-
negative, p,0.56). In addition, 70% of HIV-infected participants
had chronic skin complaints, although rarely responsible for
admission (Table 3). Admission as a result of acute exacerbation of
a chronic condition accounted for 26 (19%) and 44 (27%)
admissions in HIV-infected and HIV-negative participants,
respectively (p,0.082). Chronic lung disease and cardiac disease
were the most common serious HIV-related complications
(Table 3). In HIV-negative participants, rheumatic heart disease
was the most common chronic condition.
Causes of and Risk Factors for Death in Hospital
32/139 (23%) HIV-infected participants died in hospital
compared with 11/162 (7%) HIV-negative participants (sex- and
age-adjusted odds ratio [OR] for death for HIV-infected patients
3.7, 95% [confidence interval] CI 1.7–7.8, p,0.001). Death was
significantly associated with low CD4+ T lymphocyte count (74
versus 183 cells/ml, p,0.0029). The highest case-fatality rates
among HIV-infected participants were from HIV wasting
syndrome (53%), any malignancy (50%), and drug toxicity
(50%), and among HIV-negative participants the highest case-
fatality rates were for malignancy (83%) (Table 4).
Of the considered socio-demographic risk factors, younger age
and having a primary care-giver who was not the parent were
associated with an increased risk of death (Table 5). After adjusting
for these factors, advanced HIV disease, severe anaemia, TB
treatment in the past, poor self-rated health, a chronic disease
(except chronic skin disease), pubertal delay (Tanner puberty stage
1/2 in those aged 14 y or above), poor performance scores,
wasting, and stunting were all associated with increased risk of
death. In the final multivariate model, WHO stage 4 HIV
infection (OR 2.8, 95% CI 1.1–7.1; p,0.032), chronic disease
(OR 2.8, 95% CI 1.3–6.0; p,0.009), pubertal delay (OR 4.0, 95%
C.I 1.4–11.6; p,0.011), and poor performance scores (OR 6.9,
95% C.I 3.0–15.8; p,0.001) remained independently associated
with increased risk of death.
Discussion
The main finding of this study is that HIV is now the single most
common cause of acute admission and in-hospital death among
adolescents in Harare. HIV-infected adolescents were profoundly
immunosuppressed, and the median CD4 count (51 cells/ml) was
similar to that reported in other studies of hospitalised African
adults in the pre-ART era [20,21]. The spectrum of HIV-
associated infections was also similar to that reported in African
adults in the pre-ART era [15]. However, adolescents had an
additional and heavy burden of chronic complications—such as
growth failure and lung and cardiac disease—that have typically
been reported in vertically HIV-infected children [22–24]. In this
study, underlying chronic complications were associated with an
increased risk of in-hospital death.
We found an equal sex distribution of HIV infection, low rates
of self-reported sexual debut, and a much lower prevalence of
HSV-2 infection than would be anticipated for sexually acquired
HIV in southern Africans [25]. These findings, along with strong
associations with orphanhood and the chronic complications
discussed above, and negative association with marriage (given
that marriage at young age increases risk of HIV for young African
girls [26]), all favour long-term survival following mother-to-child
transmission as the source of HIV infection in most of our
participants. Also notable is the fact that Zimbabwe has had an
unusually good safety record for preventing percutaneous HIV
from early on in the HIV epidemic [27], and population-based
HIV prevalence surveys among older children in southern Africa
have documented substantial HIV prevalence rates with equal
gender distribution [28,29]. The widely held perception is that
HIV progresses rapidly in HIV-infected infants with a median
survival of 2 y [30], and thus survival to late childhood and
adolescence with untreated HIV has been considered extremely
unusual. Our study, however, demonstrates that long-term
survival occurs and is now a major cause of morbidity among
adolescents.
Diagnosis of HIV infection was frequently delayed in this age
group until presentation with advanced HIV disease. A substantial
minority had not been diagnosed with HIV before hospitalisation,
and most others reported relatively recent diagnosis following a
prolonged history of recurrent infections. The beneficial effects of
early diagnosis and ART on reducing the risk of opportunistic
HIV-Associated Morbidity in Adolescents
PLoS Medicine | www.plosmedicine.org 5 February 2010 | Volume 7 | Issue 2 | e1000178
Table 2. Causes of admission among adolescents admitted to hospital.
Cause of Admission (Up
to Four Causes Allowed) Condition n (%) of Participants p-Value
HIV-Infected,
n=139
HIV-Negative,
n=162
Infection 96 (69)a 30 (19)a ,0.001a
Mycobacterial disease Any mycobacterial disease 25 (18) 3 (2) —
Tuberculosisb 24 3 —
Mycobacterium avium-intracellulare disease 1 0 —
Bacterial infection Any bacterial infection 65 (47) 20 (12) —
Acute pneumonia 24 1 —
Bronchitis 9 2 —
Meningitis 9 2 —
Soft tissue or bone/joint infection 2 5 —
Enteritis 5 3 —
Urinary tract infection 1 1 —
ENT infection 0 2 —
Sexually transmitted infection 1 1 —
Blood stream infectionc 12 1 —
Organ abscessd 2 2 —
Fungal Infection Any fungal infection 35 (25) 0 (0) —
Cryptococcosis 15 0 —
Oesophageal candidiasis 21 0 —
PCP 1 0 —
Other infection Any other infection 8 (6) 10 (6) —
Malaria 2 5 —
Viral 3 3 —
Othere 3 2 —
HIV wasting syndrome 15 (11)a — —
Traumatic injury 4 (3)a 53 (33)a ,0.001
Road-traffic accident 0 19 —
Assault 1 4 —
Accident in the home 3 30 —
Complications of previous trauma 1 6 —
Overdose/other psychiatric disorder 1 (0.7)a 18 (11)a ,0.001a
Acute surgical 2 (1.4)a 15 (9)a 0.003a
Acute medical noninfectious 53 (48)a 52 (38)a 0.080a
Stroke 4 0 —
Cardiac failure 9 12 —
Exacerbation of chronic condition other than cardiac/respiratory 1 16 —
Malignancy 8 6 —
Severe anaemia (Hb,7g/dl) 34 14 —
Drug toxicityf 4 0 —
Malnutrition 3 1 —
Otherg 4 12 —
aData indicate the numbers and percentages of patients with $1 diagnosis in that category.
bHIV-infected: pulmonary, 12 (five smear-positive, one culture-positive only, six radiological); blood culture-positive, 4; TB meningitis, 2 (one with concurrent
disseminated lymphadenopathy); unilateral pleural effusion, 3; arthritis confirmed on synovial biopsy, 1; miliary shadowing, 1; abdominal para-aortic lymphadenopathy
confirmed on fine needle aspirate, 1; HIV-negative: pulmonary, 1 (smear-positive); blood culture-positive, 1; pericardial effusion, 1.
cHIV-infected: nontyphoidal Salmonella spp, 1; Staphylococcus aureus, 2; lactose-fermenting coliforms, 1; nonlactose-fermenting coliforms (except Salmonella spp), 1;
Group D Streptococcus, 1; HIV-negative: S. aureus, 1.
dHIV-infected: empyema, 2; HIV-negative: intracranial abscess, 2.
eHIV-infected: scabies, 2; self-limiting fever, 1; HIV-negative: rheumatic fever, 1, self-limiting fever, 1.
fStevens Johnsons syndrome secondary to cotrimoxazole, 2; hepatitis secondary to nevirapine, 1; lactic acidosis secondary to stavudine, 1.
gHIV-infected: anal fissures, 1; renal condition (one renal failure and one glomerulonephritis), 2; deep vein thrombosis, 1; HIV-negative: renal condition (two
glomerulonephritis and three nephrotic syndrome), 5; dysfunctional uterine bleeding, 3; gastritis, 2; hepatitis, 1; pellagra, 1.
ENT, ear, nose, and throat; PCP, pneumocystis pneumonia.
doi:10.1371/journal.pmed.1000178.t002
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infections and chronic complications, reducing mortality, and
improving growth are well-recognised in children [31]. In addition
to the high risk of irreversible complications, older age at diagnosis
and delay in starting ART may potentially result in suboptimal
immune response [32,33] and blunted catch-up growth and
pubertal development [34,35].
Although the phenomenon of long-term survival in HIV-
infected infants is well recognised in Zimbabwe, several factors
unique to this age group may be creating both demand and
supply-side barriers to diagnostic testing: in contrast to adults,
there are no free-standing counselling and testing services for
under 16-y-olds in Zimbabwe, and there are also legal barriers to
Table 3. Chronic conditions among adolescents admitted to hospital.
Chronic Condition n (%) of Participants p-Value
HIV-Infected, n=139 HIV-Negative, n=162
Chronic lung diseasea 17 (12) 0 (0) ,0.001
Cardiac disease 9 (6) 12(7) 0.72
Rheumatic heart disease 0 9 —
Cor-pulmonaleb 0 0 —
Dilated cardiomyopathy 9 1 —
Other 1 2 —
Diabetes 0 (0) 7 (4) 0.017
Epilepsy 0 (0) 3 (2) 0.093
Asthma 0 (0) 4 (2) 0.093
Chronic skin disease 97 (70) 11 (7) ,0.001
Other chronic 23 (17) 25 (15) 0.63
Neurological 7 2 —
Malignancyc 8 6 —
Haematological 1 3 —
Chronic infection/inflammation 1 5 —
Blindness 4 0 —
Polyarthritis 1 2 —
Congenital 1 7 —
aStatic radiological appearance of focal scarring, and/or opacification, and/or cystic changes, and/or bronchial wall thickening, plus negative TB smears and cultures
from current episode, plus $2 of the following: clubbing, recurrent (at least two) episodes of cough productive of copious amounts of purulent sputum in the last
3 mo, persistent fine basal crepitations, and/or wheezes on auscultation, cor pulmonale.
bMeets above case definition for chronic lung disease plus echocardiographic finding of right ventricular enlargement or $2 of the following: ascites, hepatomegaly,
raised jugular venous pressure, ankle oedema.
cHIV-infected: 4, Kaposi Sarcoma; 2, Non-Hodgkins’s lymphoma; 1, osteogenic sarcoma; 1, cholangiocarcinoma. HIV-negative: 3, haematological malignancy; 2,
intracranial tumours; 1, myxoid neurofibroma.
doi:10.1371/journal.pmed.1000178.t003
Table 4. Causes of death among adolescents admitted to hospital.
Cause of Death n (%) of Deaths n Died/Total (Case Fatality Rate)
HIV-Infected (n=32) HIV-Negative (n=11)
Tuberculosis 4 (13) 1 (9) 5/27 (19)
Pneumonia 3 (9) 1 (9) 4/25 (16)
Meningitis 2 (6) 1 (9) 3/11 (27)
Bloodstream infection 2 (6) 0 2/13 (15)
Other infectiona 1 (3) 1 (9) 2/11 (18)
Cryptococcosis 6 (19) 0 6/15 (40)
HIV wasting syndrome 8 (25) 0 8/15 (53)
Drug toxicity 2 (6) 0 2/4 (50)
Malignancy 4 (13) 5 (46) 9/14 (64)
Cardiac failure 0 2 (18) 2/21 (10)
The median time to death was 12 d (IQR 4–21 d) in HIV-infected and 10 d (IQR 6–20 d) in HIV-negative participants.
aHIV-infected, empyema; HIV-negative, osteomyelitis.
doi:10.1371/journal.pmed.1000178.t004
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testing without the permission of the legal guardian, who may be
incapacitated or absent. Reluctance of guardians to disclose the
true nature of the underlying illness was also apparent in that a
substantial minority of our HIV-infected participants had not
been told their previous test results. Clear advice to health
professionals to offer PITC and to assist guardians with disclosure
may improve timely diagnosis and adherence to subsequent ART
[36].
Our study was hospital-based and therefore likely to be biased
towards sicker patients and more severe HIV-associated
complications. One of the study sites was based at a referral
hospital, which may have resulted in a higher proportion of
specialist diagnoses such as cancer. Both hospitals had ART
clinics, but only nine (6%) of the HIV-infected participants were
admitted from these. The vast majority of our participants (87%)
were referred directly from primary health care clinics or through
Table 5. Risk factors for death among adolescents admitted to hospital (n= 301 unless specified).
Variable n Died/Total (%) Univariate OR (95% CI)a p-Value
Final Multivariate
ORb (95% CI) p-Value
Sociodemographic
Age
15–18 y 5/84 (6) 1.0 1.0
12 to ,15 y 27/129 (21) 4.2 (1.5–11.4) 0.005 2.5 (0.8–7.4) 0.11
,12 y 11/88 (13) 2.3 (0.7–6.8) 0.15 2.0 (0.6–7.0) 0.25
Primary caregiver
Biological parent 12/126 (10) 1.0 1.0
Not biological parent 31/175 (18) 2.0 (1.0–4.2) 0.05 1.3 (0.5–2.9) 0.60
Clinical
HIV WHO stage
HIV-negative 11/162 (7) 1.0 — 1.0 —
HIV-infected and stage 1/2 2/24 (8) 1.2 (0.3–5.7) 0.85 1.0 (0.2–5.7) 0.99
HIV-infected and stage 3 5/36 (14) 1.6 (0.5–5.1) 0.42 1.6 (0.5–5.4) 0.49
HIV-infected and stage 4 25/79 (32) 5.1 (2.3–11.4) 0.0001 2.8 (1.1–7.1) 0.03
Previously treated for TB
Yes 25/237 (11) 1.0 — 1.0 —
No 18/64 (28) 2.4 (1.2–4.9) 0.02 1.3 (0.6–3.2) 0.53
Poor performance score (WHO scale 3/4)
No 12/217 (6) 1.0 — 1.0 —
Yes 31/84 (37) 8.2 (3.9–17.3) 0.0001 6.9 (3.0–15.8) 0.0001
Self-perceived poor health
No 8/132 (6) 1.0 — 1.0 —
Yes 35/169 (21) 3.0 (1.3–6.9) 0.01 0.4 (0.1–1.5) 0.19
Pubertal delay (Tanner’s stage 1/2 in those $14 y)
No 34/276 (12) 1.0 — 1.0 —
Yes 9/25 (36) 3.1 (1.2–8.1) 0.021 4.0 (1.4–11.6) 0.01
Stunting (height-for-age z,22) (n = 263)
No 11/168 (7) 1.0 — 1.0 —
Yes 17/95 (18) 3.1 (1.3–7.3) 0.01 1.2 (0.5–3.2) 0.69
Wasting (weight-for-age z,22) (n = 266)
No 6/149 (4) 1.0 — 1.0 —
Yes 23/117 (20) 5.2 (2.0–13.7) 0.001 2.1 (0.6–6.9) 0.23
Chronic disease (other than skin disease)
No 22/217 (10) 1.0 — 1.0 —
Yes 21/84 (25) 2.7 (1.3–5.3) 0.005 2.8 (1.3–6.0) 0.009
Haemoglobin (n = 282)
.11g/dl 12/124 (10) 1.0 — 1.0 —
7.0–10.9 g/dl 13/110 (12) 1.0 (0.4–2.4) 0.97 0.4 (0.1–1.1) 0.07
,7.0 g/dl 14/48 (29) 3.6 (1.5–8.7) 0.005 0.8 (0.3–2.5) 0.72
aAdjusted for age group and type of primary caregiver.
bAdjusted for HIV stage, chronic disease, pubertal delay, and performance score.
doi:10.1371/journal.pmed.1000178.t005
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hospital casualty departments, and the only local alternatives to
these two hospitals are private facilities. Our results are,
therefore, likely to be representative of the pattern of acute
severe morbidity and mortality in Harare. Judging by the high
numbers of adolescents attending HIV care clinics throughout
Zimbabwe [37], our results may also be more generally
representative. Zimbabwe is unusual in having had high HIV
prevalence in antenatal clinic attendees from the early 1990s
[38], and so may be a few years ahead of other countries in the
region with respect to the subsequent epidemic of adolescent
survivors.
HIV-related morbidity and mortality, most likely reflecting
long-term survival from the paediatric HIV epidemic in the 1990s,
is now a major cause of adolescent morbidity and mortality in
Harare. Recognition of the high burden of HIV in acutely unwell
older children and adolescents is needed to stimulate earlier
diagnosis and improve access to HIV care for this previously
neglected age group. Our results strongly support implementation
of PITC for all patients in this age group attending health facilities,
ideally at the primary care as well as hospital level, so that
diagnosis is made and treatment can be started before patients are
critically ill.
Supporting Information
Text S1 Case definitions used during the present study.
Found at: doi:10.1371/journal.pmed.1000178.s001 (0.04 MB
DOC)
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Editors’ Summary
Background. Acquired immunodeficiency syndrome (AIDS)
has killed more than 25 million people since 1981, and more
than 30 million people are now infected with the human
immunodeficiency virus (HIV) that causes AIDS. HIV destroys
the cells in the immune system that normally provide
protection against disease-causing organisms. Consequently,
people infected with HIV are susceptible to so-called
opportunistic infections, including tuberculosis and
pneumonia. HIV is most commonly spread through
unprotected sex with an infected partner but another
major route of transmission is mother-to-child (vertical
transmission) during pregnancy or delivery or during breast
feeding. Mother-to-child transmission can be prevented by
giving antiviral drugs to HIV-positive mothers during their
pregnancy and to their newborn children. But, although
most mothers in developed countries have access to this
intervention, fewer than half of HIV-positive mothers in low-
and middle-income countries receive this treatment and,
every year, nearly half a million children become infected
with HIV.
Why Was This Study Done? It is generally thought that
HIV infections in infants progress rapidly and that half of the
children who acquire HIV from their mothers will die before
their second birthday if not treated with antiretroviral drugs.
However, as the AIDS epidemic matures, more children are
surviving to adolescence with untreated, vertically acquired
HIV infection in sub-Saharan Africa, the region where most
children with HIV/AIDS live. Little is known about the burden
of HIV infection and its contribution to illness and death in
adolescents in sub-Saharan Africa but this information is
needed to help health care providers prepare for this new
aspect of the AIDS epidemic. In this study, the researchers
examine the causes of acute hospital admissions (admissions
for conditions with a sudden onset and usually a short
course) among adolescents in Zimbabwe, a country where
the HIV epidemic started early and where one in seven adults
is HIV-positive and more than 17,000 children are infected
with HIV every year, mainly through vertical transmission.
What Did the Researchers Do and Find? The researchers
recruited 301 10–18-year olds who were admitted to each of
the two public hospitals in Harare (Zimbabwe) for acute
illnesses between September 2007 and April 2008. Each
patient completed a questionnaire about themselves and
their health and underwent standard investigations,
including HIV testing. Nearly half the participants were HIV
positive; about a quarter of these HIV-positive individuals
only found out about their status during the study. HIV-
positive participants were more likely to be stunted, to have
pubertal delay, and to be maternal orphans or have an HIV-
infected mother than HIV-negative participants. 69% of HIV-
positive participants were admitted to hospital because of
infections, often tuberculosis or pneumonia whereas only
19% of the HIV-negative participants were admitted for
infections. More than a quarter of all the participants had
underlying heart, lung, or other chronic conditions. Finally,
22% of the HIV-positive participants died while in hospital
compared to only 7% of the HIV-negative participants.
Factors that increased the risk of death among all the
participants were advanced HIV infection, pubertal
immaturity, and chronic conditions.
What Do These Findings Mean? These findings indicate
that HIV infection is the commonest cause of acute
adolescent admission to hospital in Harare (and probably
elsewhere in Zimbabwe). Most of these admissions are due
to opportunistic infections similar to those seen in HIV-
positive adults and to long-term complications of having
HIV/AIDS as an infant such as delayed puberty. Other
findings indicate that most of the HIV-positive adolescents
who participated in this study were infected via vertical
transmission, which supports the idea that long-term survival
after vertical infection is possible. Because the AIDS epidemic
started early in Zimbabwe, there is likely to be a lag before
adolescent survivors of vertical HIV transmission become
common elsewhere. Nevertheless, all African countries and
other places where HIV infection in adults is common need
to recognize that the burden of HIV in their acutely unwell
adolescents is likely to increase over the next few years. To
deal with this emerging aspect of the AIDS epidemic,
measures must be introduced to ensure early diagnosis of
HIV in this previously neglected age group so that treatment
can be started before HIV-positive adolescents become
critically ill.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000178.
N This study is further discussed in a PLoS Medicine
Perspective by Glenda Gray
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS, including a list of articles and other sources of
information about the primary care of adolescents with
HIV
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on the HIV and AIDS in Zimbabwe, and on children,
HIV, and AIDS (in English and Spanish)
N UNICEF also has information about children and HIV and
AIDS (in several languages)
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